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Fractures are a major clinical concern in older women and men. The most commonly considered sites of frac-
ture are the hip, spine, and wrist.1-4 About 40% of white 
women aged 50 years and older will experience at least 1 
clinically recognized fracture at one of these skeletal sites 
and be subjected to increased risks of morbidity and mor-
tality.5,6 However, other less recognized fractures, such as 
those of the pelvis, ribs, shoulder, distal femur, and proxi-
mal tibia, may also lead to reductions in quality of life.7-10 
OBJECTIVE: To examine several dimensions of health-related qual-
ity of life (HRQL) in postmenopausal women who report previous 
fractures, and to provide perspective by comparing these findings 
with those in other chronic conditions (diabetes, arthritis, lung 
disease).
PATIENTS AND METHODS: Fractures are a major cause of morbidity 
among older women. Few studies have examined HRQL in women 
who have had prior fractures and the effect of prior fracture loca-
tion on HRQL. In this observational study of 57,141 postmeno-
pausal women aged 55 years and older (enrollment from Decem-
ber 2007 to March 2009) from 17 study sites in 10 countries, 
HRQL was measured using the European Quality of Life 5 Dimen-
sions Index (EQ-5D) and the health status, physical function, and 
vitality questions of the Medical Outcomes Study 36-Item Short 
Form Health Survey (SF-36).
RESULTS: Reductions in EQ-5D health-utility scores and SF-36–
measured health status, physical function, and vitality were seen 
in association with 9 of 10 fracture locations. Spine, hip, and up-
per leg fractures resulted in the greatest reductions in quality of 
life (EQ-5D scores, 0.62, 0.64, and 0.61, respectively, vs 0.79 
without prior fracture). Women with fractures at any of these 3 
locations, as well as women with a history of multiple fractures 
(EQ-5D scores, 0.74 for 1 prior fracture, 0.68 for 2, and 0.58 for 
≥3), had reductions in HRQL that were similar to or worse than 
those in women with other chronic diseases (0.67 for diabetes, 
0.69 for arthritis, and 0.71 for lung disease).
CONCLUSION: Previous fractures at a variety of bone locations, par-
ticularly spine, hip, and upper leg, or involving more than 1 location 
are associated with significant reductions in quality of life.
Mayo Clin Proc. 2010;85(9):806-813
EQ-5D = European Quality of Life 5 Dimensions Index; GLOW = Global 
Longitudinal Study of Osteoporosis in Women; HRQL = health-related 
quality of life; SF-36 = Medical Outcomes Study 36-Item Short Form 
Health Survey
If their full health impact is to be appreciated, fractures at 
a range of sites need to be examined to determine their ef-
fects on health-related quality of life (HRQL).
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 The European Quality of Life 5 Dimensions Index (EQ-
5D) is a generic, preference-based instrument that provides 
a comprehensive framework within which to determine 
health status and measure HRQL.11,12 The EQ-5D describes 
states of health in 5 dimensions: mobility, self-care, usual 
activities, pain or discomfort, and anxiety or depression. 
The Medical Outcomes Study 36-Item Short Form Health 
Survey (SF-36) is used widely to compare the HRQL of 
general and specific populations, to estimate the burden of 
disease, and to examine the benefits of treatment interven-
tions; we used it in the current study to measure overall 
health status, physical function, and vitality.
 The purpose of our study was to examine the impact 
of common fractures on quality of life. Using data from 
participants aged 55 years and older from the Global Lon-
gitudinal Study of Osteoporosis in Women (GLOW), we 
performed a cross-sectional analysis to determine wheth-
er a history of fracture after age 45 years is associated 
with reduced HRQL, as measured by the EQ-5D instru-
ment and the physical function and vitality subscales of 
the SF-36.
PATIENTS AND METHODS
GLOW is an observational follow-up study designed to 
improve understanding of international patterns of suscep-
tibility, recognition, management, and outcomes of care in 
women 55 years and older at risk of fragility fractures. The 
study methods have been described previously13 and are 
outlined herein. Enrollment occurred between December 
2007 and March 2009.
Study Site Selection
GLOW was conducted at 723 physician practices in 17 
study sites in 10 countries in Europe, North America, and 
Australia. A scientific advisory board consisting of inves-
tigators at each of the 17 sites was constituted to provide 
scientific oversight and study management. These individ-
uals are independent, university-based investigators with 
content expertise in osteoporosis, who represent the disci-
plines of endocrinology, rheumatology, geriatric medicine, 
and epidemiology.
PhySician and Patient Selection
Practices typical of each region were recruited through pri-
mary care networks organized for administrative, research, 
or educational purposes, or by identifying all physicians in 
a geographic area. Primary care physicians were defined as 
physicians who spent the majority of their time providing 
primary health care to patients. Each physician completed 
a standardized form that collected data on personal demo-
graphics and practice characteristics.
 Practices provided lists of the names and addresses of 
women aged 55 years and older who had been seen by their 
physician in the past 24 months. These lists comprised the 
sampling frame. Sampling was stratified by age to ensure 
that two-thirds consisted of women aged 65 years and old-
er. In each practice, all eligible women aged 65 years and 
older and a random sample of half that number younger 
than 65 years were recruited.
 Patients were excluded if they were unable to complete 
the study survey because of cognitive impairment, lan-
guage barriers, institutionalization, or illness.
inStrument develoPment
Questionnaires were designed to be self-administered. 
When possible, items from published validated instruments 
were used, including the National Health and Nutrition Ex-
amination Survey,14 the EQ-5D,11,12 and the SF-36 (physical 
function and vitality components).12,15 Questions that had 
not been used previously were tested cognitively in the con-
text of the complete questionnaire in a sample of women in 
the study age group. To gauge participant comprehension 
and completion time, the complete baseline questionnaire 
was also pilot-tested before being finalized.
Survey adminiStration
Each study site obtained ethics committee approval to con-
duct the study in that location. Invitations to participate in 
the study signed by the local principal investigator together 
with baseline questionnaires were mailed to all potential 
participants. Nonrespondents were followed up with a se-
ries of postcard reminders, second questionnaires, and tele-
phone interviews.
meaSureS analyzed
Our main outcome, HRQL, was measured by the EQ-5D 
scale and the SF-36 subscales. The EQ-5D is a 5-question, 
3-response option scale. Each of the possible 243 health 
states was mapped to a country-specific preference-based 
value or utility, in which 1.00 represents full health and 
0.00 represents a state equivalent to death. The minimum 
clinically important difference in individuals with osteo-
porosis is 0.03.16 The SF-36 subscales for physical func-
tion (10 items rating degree of limitation in activities such 
as walking 100 yd to >1 mile, climbing stairs, or carrying 
groceries), vitality (4 items on perceived energy in the past 
4 weeks), and self-reported general health status (dichoto-
mized as “fair or poor” or “good, very good, or excellent”) 
were used. In the SF-36 subscales, a higher score means 
better HRQL. The minimally important difference in these 
SF-36 subscales is about 5.17
 Information on previous (since age 45 years) fractures 
of the hip, pelvis, spine, upper or lower leg, ankle, arm, 
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wrist, clavicle, or rib was collected by a list that allowed 
for more than 1 fracture location to be checked. Therefore, 
a multiple fracture designation included women who broke 
different bone types (for example, spine and hip) at the 
same or a different time. A woman who fractured the same 
bone more than once appeared on the list as a single frac-
ture (fracture at a single site).
 To provide additional perspective on the impact of frac-
tures on HRQL, scores were computed for women who 
had no previous fracture but who reported having 1 of 3 
comparison conditions: type 1 diabetes; osteoarthritis or 
rheumatoid arthritis (designated arthritis); or asthma or 
emphysema (designated lung disease).
StatiStical analySeS
Means and standard deviations are reported for continu-
ous variables (HRQL health outcomes) and percentages for 
dichotomous variables. Mean unadjusted outcomes are re-
ported for various fracture types and chronic diseases, with 
the “no fracture” group serving as a comparison. These cat-
egories are not mutually exclusive. Unadjusted means by 
fracture or disease type are age-standardized to reflect the 
age composition of the entire study population.
 To estimate comparative effects of various types of frac-
ture and chronic disease, we performed multiple linear re-
gression analyses for models of the form HRQL outcome = 
fracture type + chronic disease, adjusting for age and study 
site. We considered selected 2-way interactions among 
the 10 fracture types: spine with rib, wrist, hip, humerus, 
pelvis; wrist with hip, humerus, pelvis; hip with humerus, 
pelvis; and humerus with pelvis. Results are expressed as 
“reductions” in HRQL, which are mean adjusted differ-
ences in HRQL score for women with and without each 
condition.
RESULTS
Of the 137,151 eligible women who were mailed a ques-
tionnaire survey, 60,393 (44%) responded (56% nonre-
sponse rate). The mean ± SD age of the nonresponders was 
71±10 years vs 69±9 years for the responders (P<.001). 
Complete data were available for 57,141 (95%) of the 
60,393 responders. The participants’ mean ± SE age was 
68.66±0.04 years. Most women (76%; n=42,577) reported 
no history of fracture, 18% (n=9815) reported a single 
fracture, and 6.1% (n=3391) reported multiple fractures. 
The location of single past fractures varied in prevalence 
from 8.5% at the wrist to 1.1% at the pelvis and upper leg 
(Table 1). Low HRQL was most notable for fractures of 
the upper leg, spine, pelvis, and hip, with the age-stan-
dardized mean EQ-5D health-utility scores ranging from 
0.61 to 0.64 compared with 0.79 for women with no frac-
ture. About twice the percentage of women with these 4 
fracture types reported problems with mobility and per-
forming usual activities, compared with women without a 
previous fracture, and more than 3 times as many experi-
enced problems with self-care. In addition, about twice the 
percentage of women with these 4 fracture types said that 
TABLE 1. Health-Related Quality-of-Life Scores by Location of Prior Fracture Among 57,141 Women (Age-Standardized)a
    No fracture Clavicle Arm Wrist Rib Spine Hip Pelvis Upper leg Lower leg Ankle
    (n=42,577) (n=761) (n=1755) (n=4825) (n=2318) (n=1197) (n=1074) (n=604) (n=609) (n=1440) (n=3574)
EQ-5D health-utility 
 score,b mean ± SD 0.79±0.2 0.68±0.3 0.71±0.3 0.73±0.3 0.69±0.3 0.62±0.3 0.64±0.3 0.64±0.3 0.61±0.3 0.70±0.3 0.72±0.2
EQ-5D domains,c 
 problems with:           
  Mobility 10,953 (26) 341 (42)   752 (39) 1799 (33)   980 (40)   630 (50) 704 (59) 334 (52) 383 (64) 639 (44) 1485 (40)
 Self-care  2147 (6) 143 (16)   298 (15)   537 (10)   317 (13)   247 (20) 307 (23) 141 (20) 165 (25) 198 (13)   416 (11)
 Usual activities 10,367 (26) 336 (41)   770 (39) 1742 (33) 1035 (43)   695 (57) 624 (52) 339 (53) 347 (58) 603 (41) 1381 (37)
 Pain 28,068 (67) 582 (77) 1324 (76) 3531 (73) 1853 (80) 1041 (87) 859 (80) 494 (85) 490 (82) 1114 (78) 2754 (78)
 Anxiety or 
  depression 16,629 (40) 351 (47)   804 (48) 2093 (45) 1160 (51)   599 (52) 515 (50) 307 (53) 289 (52) 656 (47) 1672 (48)
SF-36 subscales            
  Health status 
   fair/poord    8300 (20) 265 (34)   590 (33) 1402 (28)   830 (35)   528 (45) 409 (39) 227 (39) 253 (43) 475 (33) 1110 (31)
 Physical function,e 
  mean ± SD 74±26 62±31 65±30 68±29 63±30   53±30 52±31 56±31 47±32 62±30 65±29
 Vitality,e 
  mean ± SD 61±20 55±22 55±22 58±21 54±22   50±22 53±22 52±22 51±22 55±22 55±21
a Values are No. (percentage), unless otherwise indicated. Dividing number of patients in a row by column total does not always give the age-standardized percentage 
in parentheses because age-standardized percentages reflect overall age distribution in the Global Longitudinal Study of Osteoporosis in Women, not age distribution 
for a particular fracture. EQ-5D = European Quality of Life 5 Dimensions Index; SF-36 = Medical Outcomes Study 36-Item Short Form Health Survey.
b EQ-5D: lower scores reflect poorer health.
c EQ-5D domain scores: higher scores reflect the percentage with greater difficulties.
d SF-36 health status: higher scores reflect the percentage with poorer health status.
e SF-36 physical function and vitality: lower scores reflect poorer function.
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their health was “fair or poor” (Table 1). Differences in 
frequency of reported pain and anxiety or depression were 
less dramatic, as were lower (ie, poorer function) vitality 
subscale scores. Women with a history of wrist fracture, 
the most common of the reported prior fractures, had the 
least difference for all quality-of-life measures compared 
with women with no history of fracture.
 The HRQL scores according to number of past fractures 
(none, single, or multiple) and comparison conditions (type 
1 diabetes, arthritis, and lung disease) are summarized in 
Table 2 and in the Figure. The mean EQ-5D health-utility 
scores were lower in all groups with a fracture compared 
with women with no past fracture. Disability increased 
with multiple vs single fractures. Mean age-standardized 
EQ-5D health-utility scores declined from 0.79 to 0.74 and 
0.65 for no fracture, single fracture, and multiple fractures, 
respectively. This pattern was also seen for specific deter-
minants of HRQL. About twice as many women with a his-
tory of multiple fractures vs those with no prior factures 
reported fair or poor health and problems with mobility and 
usual activities, and 3 times the number had problems with 
self-care.
 Arthritis was reported by 44% (n=24,749), lung dis-
ease by 17% (n=9576), and type 1 diabetes by 4.1% 
(n=2284) of participants. The mean EQ-5D health-utility 
scores for women with these conditions were 0.69, 0.71, 
and 0.67, respectively; 33%, 34%, and 47%, respectively, 
reported that their general health was fair or poor (Table 
2). Women with a self-reported diagnosis of osteoporosis 
appeared to have reductions in HQRL even if they had not 
had a fracture; reductions are greater in women who have 
had a fracture.
TABLE 2. Health-Related Quality-of-Life Scores by Presence of Fractures and Medical Conditions Among 57,141 Women  
(Age-Standardized; Subgroups Not Mutually Exclusive)a
 No. of fracture locations
    0 1 2 ≥3 Diabetes Arthritis Lung disease
     (n=42,577) (n=9815) (n=2425) (n=966) (n=2284) (n=24,749) (n=9576)
EQ-5D health-utility score,b mean ± SD 0.79±0.2 0.74±0.2 0.68±0.3 0.58±0.3 0.67±0.3 0.69±0.2 0.71±0.2
EQ-5D domains,c problems with:        
  Mobility 10,953 (26) 3525 (34) 1177 (46) 590 (62) 1188 (50) 10,359 (41) 3918 (41)
 Self-care  2147 (6) 966 (9)   401 (15) 262 (26)   417 (17)    2738 (11) 1050 (11)
 Usual activities 10,367 (26) 3374 (33) 1183 (46) 570 (60) 1133 (48) 10,186 (41) 3923 (41)
 Pain 28,068 (67) 7167 (73) 1945 (81) 826 (88) 1798 (80) 21,524 (88) 7442 (79)
 Anxiety or depression 16,629 (40) 4220 (44) 1202 (53) 502 (56) 1097 (50) 11,861 (49) 4704 (50)
SF-36 subscales       
  Health status fair/poord     8300 (20) 2656 (27)   884 (37) 452 (49) 1071 (47)    8155 (33) 3263 (34)
 Physical function,e mean ± SD 74±26 68±29 60±30 49±22 54±31 63±28 61±29
 Vitality,e mean ± SD 61±20 58±21 53±30 48±22 51±21 55±21 53±21
a Values are No. (percentage), unless otherwise indicated. Dividing number of patients in a row by column total does not always give the age-standardized 
percentage in parentheses because age-standardized percentages reflect overall age distribution in the Global Longitudinal Study of Osteoporosis in 
Women, not age distribution for a particular fracture or disease. EQ-5D = European Quality of Life 5 Dimensions Index; SF-36 = Medical Outcomes 
Study 36-Item Short Form Health Survey. 
b EQ-5D: lower scores reflect poorer health.
c EQ-5D domain scores: higher scores reflect the percentage with greater difficulties.
d SF-36 health status: higher scores reflect the percentage with poorer health status.
e SF-36 physical function and vitality: lower scores reflect poorer function.
FIGURE. Health-related quality-of-life scores. EQ-5D = European Quality of Life 5 Dimensions 
Index.
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 Table 3 depicts the HRQL reduction associated with 
each fracture location and comparison condition while 
controlling for age and study site. Among conditions stud-
ied, arthritis was associated with the largest reduction in 
HRQL, with reductions of 0.12, 13.9, and 8.1 points for the 
EQ-5D, physical function, and vitality scales, respectively, 
compared with women without arthritis. Type 1 diabetes; 
fractures of the spine, upper leg, and hip; and lung disease 
were also associated with decreased measures of HRQL, 
particularly for EQ-5D and physical function. Fractures 
of the wrist were associated with little disability. Table 3 
results estimate the independent contribution of each vari-
able while controlling for the others. Therefore, assuming 
no interactions exist (only 1 statistically significant inter-
action was found, for spine + rib fracture [P<.001], indi-
cating a lesser combined reduction in HRQL for women 
who fractured both than would be expected from individual 
fracture estimates), we can in theory add individual factor 
reductions to estimate the effect of having multiple con-
ditions. For example, women who fractured both an arm 
and the spine (n=121) would be expected to have an EQ-
5D reduction of 0.12 (0.03+0.09), whereas those with both 
arthritis and spine fracture (n=690) would be expected to 
have a reduction of 0.21 (0.12+0.09). We attempted to con-
firm this additive property by grouping women into 1 of 4 
groups: women with factor A alone, factor B alone, both, 
and neither. In the example of arm and spine fractures, this 
4-group classification gave an adjusted reduction estimate 
for women with both conditions of 0.11 (0.01 less than 
expected from the additive model), whereas the estimate 
for women with both spine fracture and arthritis was 0.21 
(0.01 more than expected from the model). These examples 
support our ability to add individual estimates to assess the 
effect of having more than 1 condition.
DISCUSSION
A cross-sectional view of data from this large international, 
observational study shows that women aged 55 years and 
older with a history of fracture at any of 9 different loca-
tions have a lower HRQL than women without such a his-
tory. Lower scores were most apparent for prior fractures 
of the hip and spine, but also for the upper leg. Dimensions 
of HRQL that were notably affected included mobility, 
self-care, and performance of usual activities. Lower frac-
ture-associated quality-of-life values were similar to those 
experienced by women who reported having chronic health 
conditions such as arthritis, asthma or emphysema, or type 
1 diabetes. Impaired HRQL was particularly evident for 
women with more than 1 prior fracture.
 As is often seen in clinical practice, multiple clinical 
fractures can occur in an individual. These fractures have 
an additive effect, resulting in disability similar to a single 
hip (0.07) or vertebral (0.09) fracture. For example, the 
combination of a pelvic (0.04) and rib (0.03) or arm (0.03) 
fracture has the same effect as a hip fracture. In addition, 
fractures occur in women with other comorbidities. In a 
patient with arthritis (0.12), sustaining a hip (0.07) or ver-
tebral (0.09) fracture is particularly devastating, with re-
ductions ranging from 0.19 to 0.21. Moreover, reductions 
in EQ-5D resulting from most combinations of multiple 
fractures that include hip or spine (but exclude wrist) frac-
tures match or exceed reductions due to type 1 diabetes or 
lung disease.
TABLE 3. Reductions in Health-Related Quality of Life (EQ-5D, Physical Function, and Vitality) for Women With Previous Fractures,  
Arthritis, Type 1 Diabetes, or Lung Disease Compared With Women Without Fracture History or Medical Condition,  
Adjusted for All Listed Conditions Plus Age and Study Sitea
 EQ-5D (n=51,165) Physical function (n=52,109) Vitality (n=51,962)
  Reductionb 95% CI P value Reductionb 95% CI P value Reductionb 95% CI P value
Comparison condition
 Arthritis (n=22,331)c 0.12 0.11-0.12 <.001 13.9 13.5-14.3 <.001 8.1 7.8-8.5 <.001
 Type 1 diabetes (n=1950) 0.09 0.08-0.09 <.001 14.5 13.5-15.6 <.001 7.1 6.3-8.0 <.001
 Lung disease (n=8659) 0.06 0.05-0.06 <.001   9.8   9.3-10.4 <.001 6.5 6.0-6.9 <.001
Previous fracture location 
 Spine (n=1025) 0.09 0.07-0.10 <.001 10.5   9.1-11.9 <.001 5.9 4.7-7.1 <.001
 Upper leg (n=505) 0.07 0.06-0.09 <.001 11.5   9.5-13.6 <.001 2.3 0.6-4.0 <.01
 Hip (n=905) 0.07 0.06-0.08 <.001 11.2   9.7-12.8 <.001 4.0 2.7-5.3 <.001
 Clavicle (n=661) 0.04 0.02-0.05 <.001   3.4   1.7-5.2 <.001 1.8 0.3-3.2 <.05
 Pelvis (n=512) 0.04 0.02-0.05 <.001   4.5   2.4-6.5 <.001 3.0 1.3-4.7 <.001
 Ankle (n=3123) 0.04 0.03-0.04 <.001   4.3   3.4-5.1 <.001 2.8 2.1-3.5 <.001
 Arm (n=1505) 0.03 0.02-0.04 <.001   2.1   0.9-3.3 <.001 2.3 1.3-3.3 <.001
 Rib (n=2018) 0.03 0.02-0.04 <.001   3.3   2.2-4.3 <.001 3.2 2.3-4.0 <.001
 Lower leg (n=1254) 0.03 0.02-0.04 <.001   3.0   1.7-4.3 <.001 1.3 0.2-2.3 <.05
 Wrist (n=4250) 0.01 0.001-0.01 <.05   0.1 –0.6-0.9 <.8 0.6 0.0-1.2 <.05
a EQ-5D = European Quality of Life 5 Dimensions Index; CI = confidence interval.
b Reduction in score between comparison groups (eg, with vs without diabetes).
c Numbers differ slightly for physical function and vitality because of missing data.
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 Our data are consistent with the findings of others who 
reported that HRQL is affected adversely by several types 
of fractures. After a hip fracture, mobility, ambulation, and 
self-care are significantly affected.4,18-21 This reduction in 
quality of life has been shown to persist for several years.20 
Spine fractures result in severe pain and reductions in gen-
eral health and vitality. In contrast to hip fractures, the neg-
ative impact of spine fractures occurs primarily in those 
who experienced fracture more recently.20 Although some 
improvement in HRQL may occur over time, reductions in 
quality of life are long-term.18,22
 In the current study, wrist fractures had a minimal long-
term impact on HRQL, a finding that concurs with some 
other reports.20,23 During the acute period after a wrist frac-
ture, substantial pain may develop, and movement may 
be limited. However, individuals with wrist fractures may 
experience chronic loss of function.24 In one study, older 
people with wrist fractures were reported to have trouble 
ascending and descending stairs, which may have been due 
to difficulty in holding onto the banister.21
 Less well recognized is the long-term impact of previ-
ous fractures at other bone locations. Our survey did not 
ascertain when prior fractures occurred (other than after 
age 45 years); the fracture could have occurred in the pre-
ceding year or many years in the past. Still, as a group, 
those reporting fractures of 9 of the 10 bones evaluated had 
diminished HRQL compared with their nonfracture coun-
terparts.20 The importance of this finding is underscored by 
the fact that the impact on HRQL was similar to that of 
2 medical conditions (lung disease and arthritis) that are 
more likely than past fractures to produce symptoms at the 
time of survey completion.
 Few detailed data are available that establish the asso-
ciation between fractures and utility measures. As in the 
current study, these studies focused on hip, spine, and wrist 
fractures.18,25 One study demonstrated that hip and verte-
bral fractures had a negative impact on quality-adjusted life 
years as estimated with time trade-off values using an auto-
mated computer-based instrument.26 In another study using 
the EQ-5D, Colles fractures appeared to have a minimal 
impact on quality-adjusted life years.27 The authors sug-
gested that the loss associated with a Colles fracture was 
about 2%.
 Assessments of HRQL are important for evaluating pa-
tients with osteoporosis.18,28,29 These measurements provide 
data that are necessary to better describe osteoporosis and 
the functional outcomes of this condition. Our study ex-
amines a wide variety of fractures in a population-based 
international sample of postmenopausal women.
 The major limitation of the current study was that 
fractures were self-reported and were not confirmed ra-
diographically. Nonetheless, hip and wrist fractures are 
generally reported accurately, whereas spine fractures are 
reported less accurately.30 We did not report on subclinical 
vertebral deformities because x-ray films were not a part of 
this study. It has been postulated that only severe vertebral 
deformities are associated with pain and pain-related dys-
function31 and that subclinical deformities may tend to be 
less severe. Compared with a clinically recognized defor-
mity, subclinical deformities have been shown to result in 
only a modest increase in morbidity.18
 Because no specific date of fracture was recorded, we 
were unable to account for the effect of time on quality of 
life since the fracture occurred. If we had been able to dis-
tinguish fractures that occurred more recently from those 
that occurred several years earlier, and had adjusted results 
on that basis, the effect of fractures on quality of life would 
probably have been more pronounced.
 We report quality of life associated with fractures and 
cannot infer causation or poorer health leading to fractures 
or fractures leading to poorer health. Because data on pre-
vious fractures since age 45 years were collected as a sin-
gle checklist, we are unable to determine whether multiple 
fractures occurred on single or multiple occasions. Similar-
ly, because some women may have experienced more than 
1 fracture at a specific bone location (eg, multiple rib frac-
tures in a single episode or multiple spine fractures over 
time), which would have been tallied as a single fracture, 
the rate of multiple fractures is probably underestimated. 
We compare women with or without fractures (single or 
multiple) with women with medical conditions, but we are 
unable to determine whether these medical conditions were 
accompanied by any fractures.
 Misclassification of the comparison medical conditions 
is also possible and would likely result in an underestima-
tion of their effect on quality of life. One reason for com-
bining rheumatoid arthritis and osteoarthritis was concern 
that many respondents who report the former may have the 
latter. Some patients with type 2 diabetes may have report-
ed type 1 diabetes. If this were the case, the effect of dia-
betes on HRQL would likely be underestimated. Because 
this study is cross-sectional, we cannot make inferences 
about the causality of these associations. Moreover, many 
comparisons were performed, and some results with little 
a priori evidence might have arisen by chance. Although 
several potential confounding variables were included in 
the analysis, not all risk factors may have been captured 
adequately in the GLOW data set.
CONCLUSION
The results of this large international, observational study 
demonstrate the significant effects that fractures of a va-
riety of bones have on postmenopausal women’s HRQL. 
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Particularly strong are associations for prior fractures of 
the hip, spine, and upper leg and multiple fractures of other 
bone types. Notwithstanding improvements in medical 
management of fractures, women with fractures continue 
to have lower HRQL, and these impairments need to be 
addressed.
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